OspA

Gene

Also known as: OspA

Related News

Pfizer and Valneva Lyme vaccine candidate shows more than 70% efficacy in Phase 3 VALOR trial

Apr 20, 2026

Pfizer and Valneva said their investigational Lyme disease vaccine candidate showed more than 70% efficacy in the phase 3 VALOR trial. Pfizer plans regulatory submissions after the study, which reported no safety concerns at the time of analysis.

Pfizer and Valneva report more than 70% efficacy in Phase 3 Lyme vaccine trial

Apr 04, 2026

Pfizer and Valneva said their investigational Lyme disease vaccine showed more than 70% efficacy in the Phase 3 VALOR trial with a favorable safety profile. The companies plan regulatory submissions despite the trial missing its primary statistical criterion due to fewer Lyme cases than expected.